Alivus Life Sciences Stock Screener | Share Price & Fundamental Analysis
ALIVUS
Pharmaceuticals
Share Price NSE
₹910.95
▲
20.95 (2.35%)
Share Price BSE
₹911.10
▲
21.75 (2.45%)
Track Alivus Life Sciences share price live with TickJournal's free stock screener.
Analyze Alivus Life Sciences share price history trends and compare 52-week high low
levels.
Calculate ALIVUS stock fair value using fundamental analysis and view live share price charts.
Determine Alivus Life Sciences share intrinsic value and compare it with current ALIVUS share price.
Record your Alivus Life Sciences trades in TickJournal's free trading journal and track your portfolio performance.
Alivus Life Sciences Market Cap
₹11,284.23 Cr.
ALIVUS P/E Ratio (TTM)
20.73
EPS (TTM)
₹39.63
Dividend Yield
0.54%
Debt to Equity
0.01
ALIVUS 52 Week High
₹1206.00
Alivus Life Sciences 52 Week Low
₹860.05
Operating Margin
30.00%
Profit Margin
21.25%
ALIVUS Revenue (TTM)
₹2,560.00
EBITDA
₹803.00
Net Income
₹544.00
Total Assets
₹3,411.00
Total Equity
₹2,817.00
Alivus Life Sciences Share Price History - Stock Screener Chart
Screen ALIVUS historical share price movements with interactive charts. Analyze price trends and patterns.
Alivus Life Sciences Company Profile - Fundamental Screener
Screen Alivus Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ALIVUS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE03Q201024
Alivus Life Sciences Balance Sheet Screener
Screen ALIVUS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 3,411 | 2,850 | 2,702 | 2,471 | 1,997 | 1,726 | 1,475 | 0 |
| Current Assets | 2,335 | 1,916 | 1,850 | 1,765 | 1,399 | 1,160 | 931 | 0 |
| Fixed Assets | 955 | 805 | 781 | 595 | 573 | 546 | 456 | 0 |
| Liabilities | ||||||||
| Total Liabilities | 3,411 | 2,850 | 2,702 | 2,471 | 1,997 | 1,726 | 1,475 | 0 |
| Current Liabilities | 124 | 79 | 67 | 33 | 23 | 16 | 7 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 2,817 | 2,332 | 2,138 | 2,054 | 753 | 402 | 88 | -1 |
| Share Capital | 25 | 25 | 25 | 25 | 2 | 2 | 2 | 0 |
| Reserves & Surplus | 2,793 | 2,308 | 2,114 | 2,030 | 751 | 400 | 86 | -1 |
Alivus Life Sciences Income Statement Screener - Profit & Revenue Analysis
Screen Alivus Life Sciences income statement and profit fundamentals.
Analyze ALIVUS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Alivus Life Sciences share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,560 | 2,421 | 2,295 | 2,190 | 2,138 | 1,886 | 1,549 | 887 | 0 |
| Expenses | 1,757 | 1,704 | 1,609 | 1,519 | 1,507 | 1,294 | 1,065 | 639 | 0 |
| EBITDA | 803 | 717 | 686 | 671 | 631 | 592 | 484 | 248 | 0 |
| Operating Profit % | 30.00% | 29.00% | 30.00% | 30.00% | 29.00% | 31.00% | 31.00% | 28.00% | -5.00% |
| Depreciation | 71 | 61 | 54 | 42 | 38 | 33 | 29 | 19 | 0 |
| Interest | 5 | 2 | 2 | 1 | 28 | 88 | 34 | 1 | 0 |
| Profit Before Tax | 727 | 654 | 631 | 629 | 565 | 471 | 421 | 228 | 0 |
| Tax | 181 | 169 | 160 | 162 | 146 | 119 | 108 | 33 | 0 |
| Net Profit | 544 | 486 | 471 | 467 | 419 | 352 | 313 | 196 | 0 |
| EPS | 44.30 | 39.63 | 38.43 | 38.11 | 35.63 | 32.61 | 29.04 | 24.64 | -7.89 |
Alivus Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen ALIVUS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 392 | 414 | 306 | 598 | 388 | 195 | 10 | -1 |
| Investing Activities | -616 | -117 | -147 | -122 | -69 | -51 | -9 | 0 |
| Financing Activities | -6 | -279 | -388 | -79 | -214 | -137 | 1 | 1 |
| Net Cash Flow | -230 | 18 | -228 | 397 | 106 | 8 | 2 | 0 |
Alivus Life Sciences Shareholding Pattern Screener
See Alivus Life Sciences shareholding pattern with promoter, FII, and DII holdings.
Check Alivus Life Sciences promoter holding and ownership changes for ALIVUS on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 74.99% | 74.94% | 74.91% | 74.91% | 82.85% | 82.85% | 75.00% | 75.00% |
| FII Holding | 6.57% | 6.42% | 6.84% | 5.09% | 5.01% | 4.82% | 7.85% | 6.74% |
| DII Holding | 5.19% | 5.61% | 5.47% | 7.12% | 1.40% | 1.57% | 4.16% | 4.86% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.50% | 10.34% | 10.14% | 10.21% | 9.09% | 9.13% | 10.63% | 10.99% |
| Other Holding | 2.74% | 2.69% | 2.64% | 2.67% | 1.64% | 1.64% | 2.36% | 2.41% |
| Shareholder Count | 141,977 | 138,500 | 135,643 | 132,748 | 156,183 | 149,396 | 143,960 | 146,840 |
Alivus Life Sciences Share Dividend Screener - Share Yield Analysis
Check Alivus Life Sciences dividend history with payout and yield data.
View Alivus Life Sciences dividend details including ex-dates and amounts for ALIVUS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹5.00 | 0.54% |
| 2024-March | ₹22.50 | 2.08% |
| 2023-March | ₹42.00 | 5.41% |
| 2022-March | ₹21.00 | 5.49% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Alivus Life Sciences Stock Index Membership
See which indices include Alivus Life Sciences stock.
Check ALIVUS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Alivus Life Sciences Market Events Screener - Corporate Actions
Get Alivus Life Sciences corporate actions including splits, bonuses, and buybacks.
Check Alivus Life Sciences stock events that may affect ALIVUS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 5.00 /share | -19.97% | ||
| Dividend | ₹ 10.50 /share | -14.33% | ||
| Annual General Meeting | NA | 2.88% | ||
| Annual General Meeting | NA | -1.06% | ||
| 2026-01-22 | 2026-01-22 | Quarterly Result Announcement | NA | -1.90% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -0.03% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 0.58% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 5.51% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | 5.35% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -8.51% |
| 2024-10-09 | 2024-10-09 | Change Of Name | NA | 0.00% |
| 2023-10-17 | 2023-10-17 | Dividend | ₹ 22.50 /share | 6.93% |
| 2023-03-24 | 2023-03-24 | Dividend | ₹ 21.00 /share | 7.96% |
| 2021-11-22 | 2021-11-23 | Dividend | ₹ 10.50 /share | -3.99% |
Alivus Life Sciences Competitors Screener - Peer Comparison
Screen ALIVUS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
Alivus Life Sciences Company Announcements - News Screener
Screen ALIVUS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-30 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2026-01-30 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2026-01-22 | Unaudited Financial Results For The Third Quarter And Nine Months Ended 31 December 2025. | View |
| 2026-01-22 | Board Meeting Outcome for Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2025. | View |
| 2026-01-21 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2026-01-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-14 | Closure of Trading Window | View |
| 2026-01-14 | Board Meeting Intimation for The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 2025. | View |
| 2025-12-24 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-01 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |